Skip to content

Cobicistat

Cytochrome P450 3A Inhibitor — ANTIINFECTIVES FOR SYSTEMIC USE

Also known as: GS 9350, GS-9350, tybost

OnpEMA approvedFDA approvedPMDA approvedOrphan designationATC J05AR09ATC J05AR14ATC J05AR15

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Cobicistat is an onp drug in the Cytochrome P450 3A Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2012. Its mechanism of action is classified as Breast Cancer Resistance Protein Inhibitors, Cytochrome P450 2D6 Inhibitors and Cytochrome P450 3A Inhibitors. DrugCentral lists 3 molecular targets, including CYP3A4|CYP3A5|CYP3A7|CYP3A43, REP and ABCG2. Recorded indications include Human immunodeficiency virus infection and Malignant Melanoma with BRAF V600E Mutation.

  • Approval status: onp (first approved 2012 by the FDA).
  • Drug class: Cytochrome P450 3A Inhibitor.
  • Mechanism of action: Breast Cancer Resistance Protein Inhibitors; Cytochrome P450 2D6 Inhibitors; Cytochrome P450 3A Inhibitors.
  • Molecular targets: CYP3A4|CYP3A5|CYP3A7|CYP3A43, REP and ABCG2 (3 listed in DrugCentral).
  • Indications: Human immunodeficiency virus infection and Malignant Melanoma with BRAF V600E Mutation.
  • ATC code: J05AR09 (Antivirals for treatment of HIV infections, combinations).
  • Molecular formula: C40H53N7O5S2; molecular weight 776.03 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

  • Human immunodeficiency virus infection
  • Malignant Melanoma with BRAF V600E Mutation

Off-label uses (1)

  • Coronavirus infection

Mechanism & targets

Mechanism of action (MoA)Breast Cancer Resistance Protein Inhibitors; Cytochrome P450 2D6 Inhibitors; Cytochrome P450 3A Inhibitors; Multidrug and Toxin Extrusion Transporter 1 Inhibitors; Organic Anion Transporting Polypeptide 1B1 Inhibitors; Organic Anion Transporting Polypeptide 1B3 Inhibitors; P-Glycoprotein Inhibitors
Established pharmacologic classCytochrome P450 3A Inhibitor

Molecular targets (3)

TargetGeneActionActivity
Cytochrome P450 3ACYP3A4|CYP3A5|CYP3A7|CYP3A43inhibitorKi 6.03
Replicase polyprotein 1abREPunknownKd 5.66
ATP-binding cassette sub-family G member 2ABCG2unknownIC50 4.23

Regulatory approvals (3)

DateAgencyMarketed asApplicantOrphan
2013-09-19EMA—Gilead Sciences Ireland UC
2013-03-25PMDA—Japan Tobacco Inc.Yes
2012-08-27FDA—GILEAD SCIENCES INC

ATC classification

ATC codeTherapeutic hierarchy
J05AR09ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Antivirals for treatment of HIV infections, combinations
J05AR14ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Antivirals for treatment of HIV infections, combinations
J05AR15ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Antivirals for treatment of HIV infections, combinations
J05AR18ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Antivirals for treatment of HIV infections, combinations
J05AR22ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Antivirals for treatment of HIV infections, combinations
V03AX03VARIOUS › ALL OTHER THERAPEUTIC PRODUCTS › ALL OTHER THERAPEUTIC PRODUCTS › Other therapeutic products

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Drug interaction418.3
Immune reconstitution inflammatory syndrome152.0
Foetal growth abnormality103.4
Serotonin syndrome101.3
Virologic failure98.2
Foetal exposure during pregnancy94.0
Adrenal insufficiency93.6
Gastroschisis84.6
Renal dysplasia71.4
Congenital intestinal malformation70.2
Single functional kidney67.6
Viral load increased57.4

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Cobicistat is on its molecule page.

Molecular formulaC40H53N7O5S2
Molecular weight776.03 g/mol
CAS number1004316-88-4
InChIKeyZCIGNRJZKPOIKD-CQXVEOKZSA-N
PubChem CID25151504
CC(C)C1=NC(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC2=CC=CC=C2)NC(=O)OCC2=CN=CS2)CC2=CC=CC=C2)=CS1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Cobicistat used for?

DrugCentral lists the following indications for Cobicistat: Human immunodeficiency virus infection and Malignant Melanoma with BRAF V600E Mutation.

How does Cobicistat work?

Cobicistat is classified as Breast Cancer Resistance Protein Inhibitors, Cytochrome P450 2D6 Inhibitors and Cytochrome P450 3A Inhibitors; its molecular targets in DrugCentral include CYP3A4|CYP3A5|CYP3A7|CYP3A43 (inhibitor), REP and ABCG2.

When was Cobicistat first approved?

Cobicistat was first approved by the FDA in 2012.

What drug class does Cobicistat belong to?

Cobicistat is in the Cytochrome P450 3A Inhibitor class.

What is the chemical formula of Cobicistat?

Cobicistat has the molecular formula C40H53N7O5S2 and a molecular weight of 776.03 g/mol.

Browse: all drugs starting with C · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusONP
First approval2012-08-27
AgencyFDA
Targets3
Indications2
FormulaC40H53N7O5S2
DrugCentral ID4299
Interactive profile